Study of autoimmune hepatitis in people living in Switzerland
Part of Digestive system, Immune system & allergy clinical trials.
This study looks at people with autoimmune hepatitis (an immune system condition that attacks the liver). It aims to learn more about the disease by following patients who live in Switzerland.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with autoimmune hepatitis
- Your autoimmune hepatitis is type 1 or type 2
- You currently live in Switzerland
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is building a database and collection of samples from people with autoimmune hepatitis in Italy. It aims to learn more about the disease and improve care.
This study follows people with autoimmune hepatitis (a condition where the immune system attacks the liver) and requires key blood test results at diagnosis. It may help doctors better understand this disease and how it progresses in patients in China.
This study looks at what factors affect how well the liver responds to treatment in people with autoimmune hepatitis. It may help doctors understand why some people respond better than others and could lead to more personalized care.
This study looks at fats (lipids) in the blood of people with autoimmune hepatitis to find patterns that might help diagnose or monitor the disease. It may lead to better ways to manage the condition.
This study is for people diagnosed with primary biliary cholangitis or autoimmune hepatitis. It aims to learn more about these autoimmune liver conditions and may help guide better care in the future.
This trial tests approaches to improve health outcomes for people with autoimmune liver diseases. It includes specific autoimmune conditions affecting the liver and bile ducts, and it may help your care team learn what works best for these illnesses.
Hear when a new Autoimmune Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.